UK markets close in 7 hours 40 minutes
  • FTSE 100

    7,214.81
    -2.72 (-0.04%)
     
  • FTSE 250

    23,044.12
    -9.97 (-0.04%)
     
  • AIM

    1,238.54
    -1.36 (-0.11%)
     
  • GBP/EUR

    1.1852
    +0.0000 (+0.00%)
     
  • GBP/USD

    1.3774
    -0.0019 (-0.14%)
     
  • BTC-GBP

    46,433.85
    +1,018.26 (+2.24%)
     
  • CMC Crypto 200

    1,481.14
    +17.78 (+1.22%)
     
  • S&P 500

    4,519.63
    +33.17 (+0.74%)
     
  • DOW

    35,457.31
    +198.70 (+0.56%)
     
  • CRUDE OIL

    82.33
    -0.63 (-0.76%)
     
  • GOLD FUTURES

    1,775.10
    +4.60 (+0.26%)
     
  • NIKKEI 225

    29,255.55
    +40.03 (+0.14%)
     
  • HANG SENG

    26,076.66
    +289.45 (+1.12%)
     
  • DAX

    15,552.10
    +36.27 (+0.23%)
     
  • CAC 40

    6,671.26
    +1.41 (+0.02%)
     

Could This News Spark a Turnaround for Ocugen?

·4-min read
Could This News Spark a Turnaround for Ocugen?
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Ocugen (NASDAQ: OCGN) shares were flying high earlier this year. The company signed a deal with India's Bharat Biotech for co-commercialization rights to its coronavirus vaccine candidate in the U.S. The Bharat product was close to market. Since then, Ocugen learned it wouldn't win the right to sell the vaccine in the U.S. as soon as it had hoped.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting